Currently, the main available treatments for benign prostate hyperplasia (BPH) are alpha-1 adrenergic receptor antagonists (ARAs), 5-alpha reductase inhibitors (5-αRI), anticholinergics, and Phosphodiesterase-5 inhibitors. Recent studies support the combined therapy approach using ARAs with 5-αRI for lower urinary tract symptoms (LUTS) in BPH patients at risk of clinical progression. We aimed to review BPH management in select group of randomized controlled trials by combination therapy with ARAs and 5-αRIs compared to monotherapy with either drug with respect to the safety and efficacy. A total of 6 randomized controlled trials (RCTs) involving comparison of combination therapy with monotherapy using ARAs and 5-αRIs were retrieved from Pu...
Purpose: This study compared the efficacy of an α-blocker monotherapy alone with a combination of α-...
OBJECTIVE: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
BACKGROUND:Although combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is...
Currently, the main available treatments for benign prostate hyperplasia (BPH) are alpha-1 adrenergi...
Currently, the main available treatments for benign prostate hyperplasia (BPH) are alpha-1 adrenergi...
Benign prostatic hyperplasia (BPH) is the most common condition in aging men, associated with lower ...
Prostate (glandulae prostatae) is a small gland, part of the reproductive system in males, shaped li...
Background: Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be co...
Objective: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
Benign prostatic hyperplasia (BPH) is a progressive disease that is commonly associated with bothers...
Benign prostatic hyperplasia (BPH) is a common problem in aging men, which is associated with lower ...
BackgroundAlthough combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is ...
Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) are common in elder me...
Background: Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be co...
Current guidelines for the management of benign prostatic hyperplasia (BPH) provide clear guidance o...
Purpose: This study compared the efficacy of an α-blocker monotherapy alone with a combination of α-...
OBJECTIVE: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
BACKGROUND:Although combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is...
Currently, the main available treatments for benign prostate hyperplasia (BPH) are alpha-1 adrenergi...
Currently, the main available treatments for benign prostate hyperplasia (BPH) are alpha-1 adrenergi...
Benign prostatic hyperplasia (BPH) is the most common condition in aging men, associated with lower ...
Prostate (glandulae prostatae) is a small gland, part of the reproductive system in males, shaped li...
Background: Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be co...
Objective: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
Benign prostatic hyperplasia (BPH) is a progressive disease that is commonly associated with bothers...
Benign prostatic hyperplasia (BPH) is a common problem in aging men, which is associated with lower ...
BackgroundAlthough combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is ...
Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) are common in elder me...
Background: Combination therapy with 5 alpha-reductase inhibitor (5-ARI) and alpha-blocker can be co...
Current guidelines for the management of benign prostatic hyperplasia (BPH) provide clear guidance o...
Purpose: This study compared the efficacy of an α-blocker monotherapy alone with a combination of α-...
OBJECTIVE: To investigate whether there is a difference in the risk of progressing to BPH-related pr...
BACKGROUND:Although combination therapy with 5 alpha-reductase inhibitor (5ARI) and alpha-blocker is...